Breast Cancer : Basic and Clinical Research最新文献

{"title":"Frequency of Hepatic Metastatic Disease in Patients with Stage IV Breast Cancer Is Similar for Steatotic and Non-Steatotic Livers.","authors":"Adeel Haq, Tyler J Fraum, Yu Tao, Farrokh Dehdashti, Maverick LeBlanc, Mark J Hoegger, Jingqin Luo, Katherine Weilbaecher, Lindsay L Peterson","doi":"10.1177/11782234231166476","DOIUrl":"10.1177/11782234231166476","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most common non-cutaneous malignancy and the second leading cause of cancer mortality in the United States. Breast cancer is a heterogeneous disease; diagnosis at an early stage renders it potentially curable, whereas advanced metastatic disease carries a worse prognosis.</p><p><strong>Objectives: </strong>To investigate whether hepatic steatosis (HS) is associated with liver metastases in patients with newly diagnosed stage IV female breast cancer patients (either de novo metastatic breast cancer or recurrent metastatic breast cancer) using non-contrast computed tomography (CT) as a marker of HS.</p><p><strong>Design: </strong>Retrospective analysis.</p><p><strong>Methods: </strong>We retrospectively identified 168 patients with stage IV breast cancer with suitable imaging from a prospectively maintained oncologic database. Three radiologists manually defined hepatic regions of interest on non-contrast CT images, and attenuation data were extracted. HS was defined as a mean attenuation <48 Hounsfield units. The frequency of hepatic metastatic disease was calculated for patient with and without HS. Relationships between HS and various patient (age, body mass index, race) and tumor (hormone receptor status, HER2 status, tumor grade) characteristics were also analyzed.</p><p><strong>Results: </strong>There were 4 patients with liver metastasis in the HS group (41 patients) versus 20 patients with liver metastases in the non-HS group (127 patients). The difference in frequencies of liver metastases among patients with (9.8%) versus without (15.7%) hepatic steatosis (odds ratio = 1.72 [0.53-7.39]) was not statistically significant (<i>P</i> = .45). Body mass index was significantly higher (<i>P</i> = .01) among patients with hepatic steatosis (32.2 ± 7.3 vs 28.8 ± 7.1 kg/m²). Otherwise, there were no significant differences between patients with versus without HS with respect to regarding age, race, hormone receptor status, HER2 status, or tumor grade.</p><p><strong>Conclusion: </strong>The frequency of hepatic metastatic disease in patients with stage IV breast cancer is similar for steatotic and non-steatotic livers.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231166476"},"PeriodicalIF":2.9,"publicationDate":"2023-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/e2/10.1177_11782234231166476.PMC10170590.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Effects of Indirect Coculture of Human Mesenchymal Stem Cells on the Migration of Breast Cancer Cells: A Systematic Review and Meta-Analysis.","authors":"Marie-Juliet Brown, Mhairi A Morris, Elizabeth C Akam","doi":"10.1177/11782234221145385","DOIUrl":"10.1177/11782234221145385","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is the most diagnosed cancer and the leading cause of cancer death in women globally, and mesenchymal stem cells have been widely implicated in tumour progression. This systematic review and meta-analysis seeks to identify and summarise existing literature on the effects of human mesenchymal stem cells (hMSCs) on the migration of breast cancer cells (BCCs) in vitro, to determine the direction of this relationship according to existing research and to identify the directions for future research.</p><p><strong>Methods: </strong>A systematic literature search was conducting using a collection of databases, using the following search terms: in vitro AND mesenchymal stem cells AND breast cancer. Only studies that investigated the effects of human, unmodified MSCs on the migration of human, unmodified BCCs in vitro were included. Standardised mean differences (SMDs) were calculated to determine pooled effect sizes.</p><p><strong>Results: </strong>This meta-analysis demonstrates that hMSCs (different sources combined) increase the migration of both MDA-MB-231 and MCF-7 cell lines in vitro (SMD = 1.84, <i>P</i> = .03 and SMD = 2.69, <i>P</i> < .00001, respectively). Importantly, the individual effects of hMSCs from different sources were also analysed and demonstrated that MSCs derived from human adipose tissue increase BCC migration (SMD = 1.34, <i>P</i> = .0002) and those derived from umbilical cord increased both MDA-MB-231 and MCF-7 migration (SMD = 3.93, <i>P</i> < .00001 and SMD = 3.01, <i>P</i> < .00001, respectively).</p><p><strong>Conclusions: </strong>To our knowledge, this is the first systematic review and meta-analysis investigating and summarising the effects of hMSCs from different sources on the migration of BCCs, in vitro.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234221145385"},"PeriodicalIF":1.8,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/5f/10.1177_11782234221145385.PMC9875320.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10639160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hormone Receptor-Positive / HER2-Negative Early Breast Cancer High-Risk Population: An Algorithm for Optimization Systemic Adjuvant Treatment Based on 2022 Updates.","authors":"Daniel González-Hurtado,&nbsp;Sergio Rivero,&nbsp;Juan Carlos Samamé Pérez-Vargas,&nbsp;Fernando E Petracci","doi":"10.1177/11782234231192780","DOIUrl":"https://doi.org/10.1177/11782234231192780","url":null,"abstract":"<p><p>Prognostic and predictive factors for early and late distant distance recurrence risk in estrogen-receptor positive and HER2-receptor negative early breast cancer are well known, but not all these variables work equally for the prediction. The following are the most widely accepted variables for categorizing risk levels: clinic-pathologic features (tumor size, lymph node involvement, histological grade, age, menopausal status, Ki-67 expression, estrogen, and progesterone expression), primary systemic treatment response (pathologic response and/or Ki-67 downstaging), and gene expression signatures stratification. Treatment guidelines from cancer societies and collaborative groups, online predict-tools, real-world data and experts' opinion recommends different adjuvant strategies (chemotherapy, endocrine therapy, ovarian suppression, olaparib, or abemaciclib) depending on the low (< 10%), intermediate (10%-20%) or high-risk of distance recurrence at least in the first 5 years. Multiple randomized prospective trials were updated in 2022, that evidence allow us to perform a stratification of risk in pre- and postmenopausal women with estrogen-receptor positive and HER2-receptor negative early breast cancer based on a combination of clinic-pathologic features and genomic assays and guide the adjuvant systemic treatment recommendation for those with high risk.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231192780"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/1c/10.1177_11782234231192780.PMC10450458.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10465132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>TP53</i> Signature Can Predict Pathological Response From Neoadjuvant Chemotherapy and Is a Prognostic Factor in Patients With Residual Disease.","authors":"Shin Takahashi,&nbsp;Keiju Sasaki,&nbsp;Chikashi Ishioka","doi":"10.1177/11782234231167655","DOIUrl":"https://doi.org/10.1177/11782234231167655","url":null,"abstract":"<p><strong>Background: </strong>The <i>TP53</i> signature that predicts the mutation status of <i>TP53</i> has been shown to be a prognostic factor and predictor of neoadjuvant chemotherapy (NAC) response.</p><p><strong>Objectives: </strong>The current study sought to investigate the utility of the <i>TP53</i> signature for predicting pathological complete response (pCR) and its prognostic significance among patients with residual disease (RD).</p><p><strong>Design: </strong>The study followed a retrospective cohort study design.</p><p><strong>Methods: </strong>Patients with T1-3/N0-1 from a cohort of those with HER2-negative breast cancer who received NAC were selected. Ability to predict pCR was evaluated using odds ratio, positive and negative predictive values, sensitivity, and specificity. Prognostic factors in the RD group were explored using the Cox proportional hazards model with distant recurrence-free survival (DRFS). Four independent cohorts were used for validation.</p><p><strong>Results: </strong>A total of 333 eligible patients were classified into the <i>TP53</i> mutant signature (n = 154) and wild-type signature (n = 179). Among the molecular and pathological factors, the <i>TP53</i> signature had the highest predictive power for pCR. In 4 independent cohorts (n = 151, 85, 104, and 67, respectively), pCR rate in <i>TP53</i> mutant signature group was significantly higher than that in the wild-type group. Univariate and multivariate analyses on DRFS in the RD group identified the <i>TP53</i> signature and nodal status as independent prognostic factors, with the former having a better hazard ratio than the latter. After comparing DRFS between 3 groups (pCR, RD/<i>TP53</i> wild-type signature, and RD/<i>TP53</i> mutant signature groups), the RD/<i>TP53</i> mutant signature group showed significantly worse prognosis compared with others. The RD/<i>TP53</i> wild-type signature group did not exhibit inferior DRFS compared with the pCR group.</p><p><strong>Conclusion: </strong>Our results showed that the <i>TP53</i> mutant signature can predict pCR and that combining pathological response and <i>TP53</i> mutant signature allows for the identification of subgroups with truly poor prognosis.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231167655"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/10/26/10.1177_11782234231167655.PMC10170595.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10290147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iopromide for Contrast-Enhanced Mammography: A Systemic Review and Meta-Analysis of Pertinent Literature.","authors":"Jan Endrikat,&nbsp;Hassan Khater,&nbsp;Alexander Dp Boreham,&nbsp;Sabine Fritze,&nbsp;Carsten Schwenke,&nbsp;Aasia Bhatti,&nbsp;Zuzana Jirakova Trnkova,&nbsp;Peter Seidensticker","doi":"10.1177/11782234231189467","DOIUrl":"https://doi.org/10.1177/11782234231189467","url":null,"abstract":"<p><strong>Background: </strong>Contrast-enhanced mammography (CEM) is an emerging breast imaging modality. Clinical data is scarce.</p><p><strong>Objectives: </strong>To summarize clinical evidence on the use of iopromide in CEM for the detection or by systematically analyzing the available literature on efficacy and safety.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Data sources and methods: </strong>Iopromide-specific publications reporting its use in CEM were identified by a systematic search within Bayer's Product Literature Information (PLI) database and by levering a recent review publication. The literature search in PLI was performed up to January 2023. The confirmatory-supporting review publication was based on a MEDLINE/EMBASE + full text search for publications issued between September 2003 and January 2019. Relevant literature was selected based on pre-defined criteria by 2 reviewers. The comparison of CEM vs traditional mammography (XRM) was performed on published results of sensitivity and specificity. Differences in diagnostic parameters were assessed within a meta-analysis.</p><p><strong>Results: </strong>Literature search: A total of 31 studies were identified reporting data on 5194 patients. Thereof, 19 studies on efficacy and 3 studies on safety. Efficacy: in 11 studies comparing iopromide CEM vs XRM, sensitivity was up to 43% higher (range 1%-43%) for CEM. Differences in specificity were found to be in a range of -4% to 46% for CEM compared with XRM. The overall gain in sensitivity for CEM vs XRM was 7% (95% CI [4%, 11%]) with no statistically significant loss in specificity in any study assessed. In most studies, accuracy, positive predictive value, and negative predictive value were found to be in favor of CEM. In 2 studies comparing CEM with breast magnetic resonance imaging (bMRI), both imaging modalities performed either equally well or CEM tended to show better results with respect to sensitivity and specificity. Safety: eight cases of iopromide-related adverse drug reactions were reported in 1022 patients (0.8%).</p><p><strong>Conclusions: </strong>Pertinent literature provides evidence for clinical utility of iopromide in CEM for the detection or confirmation of breast cancer. The overall gain in sensitivity for iopromide CEM vs XRM was 7% with no statistically significant loss in specificity.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231189467"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a3/69/10.1177_11782234231189467.PMC10433886.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10651368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Educational Intervention Based on Theory of Planned Behavior (TPB) on Doing Breast Self-examination in a Sample of Iranian Women.","authors":"Ali Khani Jeihooni,&nbsp;Zahra Sadat Moayedi,&nbsp;Victoria Momenabadi,&nbsp;Farzaneh Ghalegolab,&nbsp;Pooyan Afzali Harsini","doi":"10.1177/11782234221145417","DOIUrl":"https://doi.org/10.1177/11782234221145417","url":null,"abstract":"<p><strong>Background: </strong>Breast self-examination (BSE) is an important part of health care for all women in every stage of life. This study aimed to investigate the effect of theory of planned behavior (TPB) on doing BSE in a sample of Iranian women.</p><p><strong>Methods: </strong>A cross-sectional study was carried out to examine the factors affecting the BSE in 400 women. Then, a quasi-experimental study was conducted on 200 subjects (100 in experimental group and 100 in control group). The educational intervention for the experimental group consisted of 8 training sessions. A questionnaire including demographic characteristics, knowledge, and constructs of TPB was used to measure BSE performance before and 6 months after the intervention. Constructs of attitude, subjective norms, and perceived behavioral control predicted the intention to do the BSE.</p><p><strong>Results: </strong>The mean age of the subjects was 31.65 ± 7.59 years. The studied variables predicted 38.7% of behavioral intention (<i>P</i> < .001, odds ratio = 0.387). Six months after the intervention, the experimental group showed a significant increase in the knowledge, attitude, perceived behavioral control, subjective norms, intention, and BSE performance compared with the control group (<i>P</i> < .001).</p><p><strong>Conclusions: </strong>This study showed that educational intervention based on the TPB was effective in promoting breast cancer screening behavior such as BSE. Therefore, it is suggested that health educators and health care planners use educational texts based on these constructs of TPB to increase their influence on individuals via screening behavior for breast cancer.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234221145417"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/fd/10.1177_11782234221145417.PMC9884953.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10696623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Potential Diagnostic Role of the Lnc-MIAT, miR-29a-3p, and FOXO3a ceRNA Networks as Noninvasive Circulatory Bioindicator in Ductal Carcinoma Breast Cancer.","authors":"Shokufeh Razi,&nbsp;Hossein Mozdarani,&nbsp;Roudabeh Behzadi Andouhjerdi","doi":"10.1177/11782234231184378","DOIUrl":"https://doi.org/10.1177/11782234231184378","url":null,"abstract":"<p><strong>Background: </strong>Over the last few decades, tremendous progress has been achieved in the early detection and treatment of breast cancer (BC). However, the prognosis remains unsatisfactory, and the underlying processes of carcinogenesis are still unclear. The purpose of this research was to find out the relationship between myocardial infarction-associated transcript (<i>MIAT</i>), <i>FOXO3a</i>, and <i>miRNA29a-3p</i> and evaluated the expression levels in patients compare with control and their potential as a noninvasive bioindicator in whole blood in BC.</p><p><strong>Methods: </strong>Whole blood and BC tissue are taken from patients before radiotherapy and chemotherapy. Total RNA was extracted from BC tissue and whole blood to synthesize complementary DNA (cDNA). The expression of <i>MIAT, FOXO3a</i>, and <i>miRNA29a</i>-<i>3p</i> was analyzed by the quantitative reverse transcription-polymerase chain reaction (RT-qPCR) method and the sensitivity and specificity of them were determined by the receiver operating characteristic (ROC) curve. Bioinformatics analysis was used to understand the connections between <i>MIAT, FOXO3a</i>, and <i>miRNA29a</i>-<i>3p</i> in human BC to develop a ceRNA (competitive endogenous RNA) network.</p><p><strong>Results: </strong>We identified that in ductal carcinoma BC tissue and whole blood, <i>MIAT</i> and <i>FOXO3a</i> were more highly expressed, whereas <i>miRNA29a</i>-<i>3p</i> was lower compared with those in nontumor samples. There was a positive correlation between the expression levels of <i>MIAT, FOXO3a</i>, and <i>miRNA29a</i>-<i>3p</i> in BC tissues and whole blood. Our results also proposed <i>miRNA29a</i>-<i>3p</i> as a common target between <i>MIAT</i> and <i>FOXO3a</i>, and we showed them as a ceRNA network.</p><p><strong>Conclusions: </strong>This is the first study that indicates <i>MIAT, FOXO3a</i>, and <i>miRNA29a</i>-<i>3p</i> as a ceRNA network, and their expression was analyzed in both BC tissue and whole blood. As a preliminary assessment, our findings indicate that combined levels of <i>MIAT, FOXO3a</i>, and <i>miR29a</i>-<i>3p</i> may be considered as potential diagnostic bioindicator for BC.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231184378"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/e5/10.1177_11782234231184378.PMC10331106.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10300877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Side Effects and Its Management in Adjuvant Endocrine Therapy for Breast Cancer: A Matter of Communication and Counseling.","authors":"Aina Johnsson,&nbsp;Kerstin Fugl-Meyer,&nbsp;Pal Bordas,&nbsp;Janet Åhman,&nbsp;Anna Von Wachenfeldt","doi":"10.1177/11782234221145440","DOIUrl":"https://doi.org/10.1177/11782234221145440","url":null,"abstract":"<p><strong>Objective: </strong>Women with a newly diagnosed hormone receptor-positive breast cancer are offered adjuvant endocrine therapy (AET). Although the treatment reduces the risk of relapse and death not all women are adherent to it. Many factors, including the therapy's menopausal side effects, can adversely affect adherence to the treatment. This study explores the extent to which women treated with AET perceived that health care providers addressed their side effects.</p><p><strong>Methods: </strong>Ten focus groups were set up, containing between four to nine women. In total, 58 women participated in the study-45 from the Stockholm metropolitan region and 13 from the scarcely populated Norrbotten region. The interviews were analyzed using qualitative content analysis with an inductive approach.</p><p><strong>Results: </strong>The women were usually satisfied with the care they received from the health care providers. However, their experiences were more complex when it came to their satisfaction with the care in terms of the menopausal side effects of therapy, sexuality in particular. The participants reported that their healthcare providers rarely asked about sex life-related side effects of the treatment.</p><p><strong>Conclusions: </strong>Health care providers need to communicate and consult about issues related to their patients' sex lives following their breast cancer diagnosis and during their treatment.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234221145440"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10623248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Breast Cancer Progression after Treatment in the Western Region of Saudi Arabia.","authors":"Majed Ramadan,&nbsp;Rwiah Alsiary,&nbsp;Noor Alsaadoun,&nbsp;Noara Alhusseini,&nbsp;Muhammad Raihan Sajid,&nbsp;Noor Mohamed Hamed,&nbsp;Tarek Ziad Arabi,&nbsp;Belal Nedal Sabbah","doi":"10.1177/11782234231158270","DOIUrl":"https://doi.org/10.1177/11782234231158270","url":null,"abstract":"<p><strong>Background: </strong>The risk of breast cancer progression is one of the most difficult factors to predict as it is studied in different populations, patient groups, or time frames, resulting in conflicting estimates of incidence rates reported in the literature. The purpose of this study is to identify predictive factors for breast cancer recurrences in a sample of the Middle Eastern population.</p><p><strong>Methodology: </strong>A cohort retrospective study included all eligible breast cancer patients at the National Guard Health Affairs (NGHA) Hospital in Jeddah, Western region, from 2015 to 2021. Our primary outcome was the progression status of the patients; we adjusted for demographic, clinical, and molecule characteristics of the population. From 2015 to 2021, there were 319 patients diagnosed with breast cancer. Multiple logistic regression analysis was used to estimate predictors of breast cancer progression.</p><p><strong>Results: </strong>One of five breast cancer patients had breast cancer progression (20.83%), while 66.15% of the progression patients were between the ages of 41-65. In multivariate analysis, age, progesterone receptor (PR), family history, and tumor size were significant predictors of breast cancer progression. The age group of 20-40 years was a protective predictor of breast cancer progression, patients in the young age group were less likely to be diagnosed with progression (OR = 0.35; CI = 0.15, 0.81). While negative PRs and tumor size greater than 2 cm were significant predictor factors of breast cancer progression (OR = 2.07; CI = 1.09, 3.91, OR = 2.02; CI = 1.9, 3.78).</p><p><strong>Conclusion: </strong>Although the effect of young age as a protective factor for the progression of breast cancer remains controversial, our study revealed that patients between 41 and 60 years of age had a higher rate of progression. Future larger prospective studies are needed to delineate the role of age and PR hormone receptors in determining the best treatment options for women with breast cancer in the Saudi population.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231158270"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/af/10.1177_11782234231158270.PMC10061810.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9296643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Endocrine Agents should be the Dominant Systemic Therapies Prescribed in Luminal A Breast Cancer.","authors":"Matthew G Davey,&nbsp;Michael J Kerin","doi":"10.1177/11782234221145409","DOIUrl":"https://doi.org/10.1177/11782234221145409","url":null,"abstract":"outcomes for premenopausal women who develop metastatic LABC","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234221145409"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/c7/10.1177_11782234221145409.PMC9841871.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10541946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}